Država: Južnoafrička Republika
Jezik: engleski
Izvor: South African Health Products Regulatory Authority (SAHPRA)
Xixia
CLAMENTIN 375 (Tablets) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): CLAMENTIN 375 (Tablets) COMPOSITION: CLAMENTIN 375: White/off-white round, film coated tablets containing amoxycillin trihydrate equivalent to 250 mg amoxycillin and potassium clavulanate equivalent to 125 mg clavulanic acid . PHARMACOLOGICAL CLASSIFICATION: A 20.1.2 Penicillins PHARMACOLOGICAL ACTION: (a) Bacteriology: (i) Spectrum: CLAMENTIN is the group name for formulations containing 2, 4 and 5 parts of a broad spectrum penicillin, amoxycillin and 1 part of potassium clavulanate. Potassium clavulanate has been shown in vitro to be an irreversible inhibitor of beta-lactamases produced by; Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Haemophilus influenzae, Neisseria gonorrhoeae and Bacteroides fragilis. Potassium clavulanate does not inactivate the chromosomally mediated (Sykes Type 1 Cephalosporinase) beta-lactamases produced by Acinetobacter species, Citrobacter species, Enterobacter, Indole positive Proteus, Providencia species and Serratia marcescens. In vitro the formulation showed synergism against amoxycillin-resistant organisms, with no evidence of antagonism and the activity was not reduced in the presence of serum. (In vitro activity does not necessarily imply in vivo efficacy). (ii) Bactericidal action: The amoxycillin component of the formulations exert a bactericidal action against many strains of Gram-positive and Gram-negative organisms. The clavulanic acid component has very little bactericidal action. It does however, by inactivation of susceptible beta-lactamases, protect amoxycillin from degradation by a large number of beta-lactamase enzymes produced by penicillin resistant strains of organisms. (b) Absorption: The pharmacokinetics Pročitajte cijeli dokument